In this study, a clinical trial was carried out to analyze the effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer patients and specify the relationship between the combined modality and occurrence and progression of tumor, so as to provide a new idea for treatment and prognosis of patients. This evidence concerns the gene CXCR4 and ovarian carcinoma.